Q-omics provides the consensus-scored ZNF169 profile across patient tissues and cancer cell-line models. ZNF169 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ZNF169 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ZNF169 RNA expression shows 21,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where ZNF169 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF169 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF169 survival associations across molecular data types. ZNF169 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF169 RNA expression–survival associations across cancer types. High ZNF169 expression shows unfavorable associations in ACC, KIRC and LIHC, but favorable associations in BLCA, SKCM and BRCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ZNF169 RNA expression.
This table summarizes ZNF169 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF169. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF169 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, CHOL and STAD. The HNSC box plot shows higher ZNF169 RNA expression in tumor versus normal tissue (log2 FC = +0.449, t-test p < 0.001).
This table shows molecular features associated with ZNF169 in patient tissues and cancer cell lines. In patient samples, ZNF169 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF169 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
